Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor‐containing regimen

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Hepatology Research

• Publication date

  2018-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/hepr.13074PMID 29504692
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study

  2018cited by this paper
• Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

  2017cited by this paper
• Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan

  2017cited by this paper
• Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens

  2017cited by this paper
• Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy

  2017cited by this paper
• EASL Recommendations on Treatment of Hepatitis C 2016.

  2017cited by this paper
• Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

  2017cited by this paper
• Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

  2017cited by this paper
• Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan

  2017cited by this paper
• Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.

  2017cited by this paper
• Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.

  2016cited by this paper
• Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure

  2016cited by this paper
• Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents

  2016cited by this paper
• Development of rare resistance‐associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two‐hit mechanism

  2016cited by this paper
• Recommendations on Treatment of Hepatitis C 2015

  2015cited by this paper
• Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

  2015cited by this paper
• Recommendations on Treatment of Hepatitis C 2018 q European Association for the Study of the Liver ⇑

  2015cited by this paper
• Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection

  2014cited by this paper
• Viral hepatitis and the Global Burden of Disease: a need to regroup

  2013cited by this paper
• Guidelines for the Management of Hepatitis C Virus Infection

  2013cited by this paper
• Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence

  2013cited by this paper
• Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

  2010cited by this paper
• FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest

  2007cited by this paper

• Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients.

  2026cites this paper
• [Prevalence and molecular genetic characteristics of parenteral hepatitis B, C and D viruses in HIV positive persons in the Novosibirsk region].

  2022cites this paper
• WITHDRAWN: Analysis of host genetic variations associated with response to anti-HCV therapies in global populations

  2021cites this paper
• Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy

  2020cites this paper
• Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection

  2020cites this paper
• Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all‐oral direct antiviral therapy

  2019cites this paper
• Rescue therapy for chronic hepatitis C virus infection after repeated treatment failures: Impact on disease progression and risk of hepatocellular carcinoma

  2019cites this paper
• Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report

  2019cites this paper
• Favorable outcome of retreatment by direct‐acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure

  2019cites this paper
• NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors

  2019cites this paper
• Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus

  2018cites this paper